Viramune cleared for use in combination with protease inhibitors.
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D019258:Saquinavir / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D019829:Nevirapine; D019258:Saquinavir; D019438:Ritonavir